SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bluejeans who wrote (30039)1/9/2000 11:58:00 PM
From: Torben Noerup Nielsen  Respond to of 32384
 
Bluejeans,

Thanks. That's a fairly high number. I wonder if part of last week's action was shorts. At times, was flipping back and forth with a downtick immediately followed by an uptick and then the whole thing cycled again. It'll be interesting to see if the short position has grown by the time the next report comes out.

It may be interesting to note that the short position is comparable to the number of outstanding warrants so some of this could be people who hold the warrants but couldn't sell them since that's a relatively illiquid market.

If there's real news coming out, we might get a bit of a short squeeze. There're enough to generate a few points if it does take off.

Thanks, Torben



To: bluejeans who wrote (30039)1/10/2000 8:41:00 AM
From: Henry Niman  Respond to of 32384
 
The $10 million in cash from the sale of Marathon should help LGND bolster its sales efforts. Looks like pulling out all stops to get Targretin word out. I think that the focus is profitability this year and a real increase in shareholder value. I believe that 5 press releases in a week is a LGND record.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News